Skip to main content

Table 5 Incremental change in DAS28-ESR and DAS28-CRP at 6 months after LOT initiation

From: Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Antibody Status From 6 months
Abatacept Other bDMARD Incremental difference
Cohort (n) Mean 95% CI Cohort (n) Mean 95% CI LS Mean 95% CI P value
DAS28-ESR
 All patients 92 −1.59 −1.95,-1.23 145 −1.56 − 1.87,-1.24 − 0.04 − 0.45,0.38 0.86
 ACPA+ 48 −1.58 −2.09,-1.06 60 − 1.21 −1.71,-0.71 −0.37 − 0.97,0.24 0.24
 ACPA- 20 −2.03 −2.96,-1.09 30 −1.92 −2.79,-1.05 − 0.11 − 0.94,0.73 0.81
 RF+ 65 −1.57 −2.00,-1.15 94 −1.39 − 1.78,-1.00 −0.19 −0.69,0.32 0.47
 RF- 21 −1.73 −2.59,-0.86 34 −2.01 − 2.83,-1.18 0.28 −0.51,1.08 0.49
 ACPA+/RF+ 45 −1.58 −2.10,-1.05 47 − 1.10 − 1.61,-0.59 −0.48 − 1.11,0.15 0.14
 ACPA+/RF- a −2.59 −36.06,30.88 a −2.35 − 54.75,50.05 −0.24 −5.27,4.79 0.93
 ACPA−/RF+ a −2.55 −4.73,-0.37 6 −1.28 −3.22,0.66 − 1.27 − 3.14,0.60 0.22
 ACPA−/RF- 16 −1.88 −2.82,-0.93 24 −2.02 −2.91,-1.12 0.14 −0.76,1.04 0.76
DAS28-CRP
 All patients 116 −1.55 − 1.82,-1.28 106 −1.39 − 1.68,-1.09 −0.16 − 0.50,0.18 0.36
 ACPA+ 48 −1.49 − 1.94,-1.05 42 −1.20 − 1.71,-0.69 −0.29 − 0.83,0.24 0.28
 ACPA- 11 −1.28 −2.22,-0.35 21 −1.14 −1.88,-0.40 −0.14 − 1.22,0.93 0.80
 RF+ 87 −1.66 −1.97,-1.35 69 −1.43 − 1.80,-1.06 − 0.23 − 0.64,0.18 0.27
 RF- 17 −1.25 −2.04,-0.47 25 −1.48 −2.21,-0.76 0.23 −0.67,1.13 0.62
 ACPA+/RF+ 44 −1.50 −1.94,-1.06 38 −1.04 − 1.55,-0.53 −0.46 −1.02,0.11 0.12
 ACPA+/RF- a −2.06 −13.11,9.00 a −2.80 −19.06,13.46 0.74 −2.47,3.96 0.69
 ACPA−/RF+ a −3.10 −4.32,-1.89 6 −0.88 −1.97,0.22 −2.22 − 3.64,-0.81 0.01
 ACPA−/RF- 6 0.18 −1.02,1.38 15 −1.11 −1.94,-0.29 1.30 −0.08,2.67 0.07
  1. bDMARD Biologic disease-modifying antirheumatic drugs, CI Confidence interval, CRP c-reactive protein, DAS Disease activity score, ESR Erythrocyte sedimentation rate; n is the number of patients with a DAS score recorded at LOT initiation and at 6 months
  2. aCells suppressed due to small numbers